A prescription drug may travel from a manufacturer to a distributor and then to a pharmacy or hospital without ever reaching a patient. If that unopened product is returned, it cannot simply be placed back into inventory. The company accepting the return must determine whether the product is eligible for resale and confirm that its physical identity agrees with the records created during its original distribution.
New guidance published by GS1 US in September 2026 gives pharmaceutical trading partners a common framework for handling these saleable returns. It covers return authorization, product verification, transaction-record association, exception management and reconciliation under the Drug Supply Chain Security Act, or DSCSA.
The product identifier printed during packaging plays a central role in this process.
Prescription drug packages commonly carry a GS1 DataMatrix containing the product’s Global Trade Item Number, serial number, lot number and expiration date. The GTIN incorporates the National Drug Code for the product. The serial number distinguishes that individual package from every other package carrying the same drug information.
When a product is returned, the DataMatrix can be scanned to capture those identifiers. The accepting trading partner then compares the physical package with the serialized data and transaction records associated with its original movement through the supply chain.
FDA guidance explains that the company accepting a saleable return must be able to associate it with the correct Transaction Information and Transaction Statement. For a wholesale distributor, the product identifier must also be verified before the returned drug is distributed again. This helps confirm that the returned package is the same one previously supplied to the organization sending it back.
The barcode does not make that determination by itself. It provides the identifier that connects the physical package to the corresponding electronic records. If the code is unreadable, contains incorrect data or identifies a package that cannot be found in the transaction history, the return becomes an exception that requires investigation.
That is why barcode quality during the original packaging run matters long after the product leaves the facility.
A DataMatrix may appear complete to the human eye while still containing damaged cells, insufficient contrast or poor spacing that makes it difficult for a scanner to decode. A code can also be printed clearly while carrying the wrong serial number because of a data-handling or product-tracking error. Both problems can prevent a legitimate returned product from being reconciled efficiently.
Inline inspection allows a packaging operation to read each DataMatrix immediately after it is printed. The system can confirm that the code is readable, compare its contents with the assigned production record and identify a defective package before it moves farther down the line. Inspection is especially important when every package receives a different serial number.
A returned pharmaceutical product may arrive months after it was originally packaged. By then, the printed DataMatrix is the most direct connection between the physical package and the serialized records maintained by manufacturers, distributors and dispensers.
Clean printing and accurate data do more than help a drug package pass inspection on production day. They help the pharmaceutical supply chain determine whether that same package can safely and legally be sold again.